Free Trial
NASDAQ:VERV

Verve Therapeutics (VERV) Stock Price, News & Analysis

Verve Therapeutics logo
$5.43 -0.07 (-1.27%)
As of 11:23 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Verve Therapeutics Stock (NASDAQ:VERV)

Key Stats

Today's Range
$5.43
$5.68
50-Day Range
$2.97
$6.71
52-Week Range
$2.86
$9.31
Volume
414,755 shs
Average Volume
1.77 million shs
Market Capitalization
$484.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.75
Consensus Rating
Buy

Company Overview

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Verve Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

VERV MarketRank™: 

Verve Therapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 685th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Verve Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Verve Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Verve Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Verve Therapeutics are expected to decrease in the coming year, from ($2.49) to ($2.83) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Verve Therapeutics is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Verve Therapeutics is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Verve Therapeutics has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Verve Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    25.05% of the float of Verve Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Verve Therapeutics has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Verve Therapeutics has recently decreased by 0.42%, indicating that investor sentiment is improving.
  • Dividend Yield

    Verve Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Verve Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    25.05% of the float of Verve Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Verve Therapeutics has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Verve Therapeutics has recently decreased by 0.42%, indicating that investor sentiment is improving.
  • News Sentiment

    Verve Therapeutics has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Verve Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    19 people have searched for VERV on MarketBeat in the last 30 days. This is an increase of 850% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added Verve Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Verve Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,427.00 in company stock.

  • Percentage Held by Insiders

    19.30% of the stock of Verve Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    97.11% of the stock of Verve Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Verve Therapeutics' insider trading history.
Receive VERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VERV Stock News Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
J.P. Morgan Sticks to Their Hold Rating for Verve Therapeutics (VERV)
Verve Therapeutics price target raised to $24 from $18 at Guggenheim
See More Headlines

VERV Stock Analysis - Frequently Asked Questions

Verve Therapeutics' stock was trading at $5.64 at the beginning of 2025. Since then, VERV stock has decreased by 0.8% and is now trading at $5.5950.
View the best growth stocks for 2025 here
.

Verve Therapeutics, Inc. (NASDAQ:VERV) released its earnings results on Thursday, February, 27th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.14. The company earned $13.08 million during the quarter, compared to analyst estimates of $3.94 million. Verve Therapeutics had a negative trailing twelve-month return on equity of 35.23% and a negative net margin of 807.65%.

Verve Therapeutics (VERV) raised $201 million in an initial public offering on Thursday, June 17th 2021. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair served as the underwriters for the IPO.

Verve Therapeutics' top institutional shareholders include Bank of New York Mellon Corp (0.25%), Rhumbline Advisers (0.12%), Green Alpha Advisors LLC (0.06%) and GAMMA Investing LLC (0.04%). Insiders that own company stock include Krishna Yeshwant, Fmr Llc, Andrew D Ashe, Sekar Kathiresan, Burt A Adelman, Joan Nickerson, Allison Dorval, Andrew Bellinger and 2017 Gp LLC Gv.
View institutional ownership trends
.

Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Verve Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

Last Earnings
2/27/2025
Today
5/02/2025
Next Earnings (Estimated)
5/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VERV
Fax
N/A
Employees
110
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.75
High Stock Price Target
$39.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+368.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-200,070,000.00
Net Margins
-807.65%
Pretax Margin
-806.39%

Debt

Sales & Book Value

Annual Sales
$32.33 million
Price / Cash Flow
N/A
Book Value
$7.31 per share
Price / Book
0.75

Miscellaneous

Free Float
68,324,000
Market Cap
$490.29 million
Optionable
Optionable
Beta
1.86
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:VERV) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners